All Stories

Market volatility compounds ‘already challenging’ year for biotech IPOs

The market turbulence unleashed by President Donald Trump’s tariff policies will likely dry up the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.

Apr 11, 2025 - 15:37
 0
Market volatility compounds ‘already challenging’ year for biotech IPOs
The market turbulence unleashed by President Donald Trump’s tariff policies will likely dry up the trickle of biotech IPOs that were expected in 2025, a capital markets expert has told Fierce.
Read More

Tags:

Previous Article

Fierce Pharma Asia—Congress' US-China biotech report; NIH's database ban; GSK's ...

Next Article

Human medicines European public assessment report (EPAR): Effentora, fentanyl, D...

Related Posts

Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal

Teleflex plays musical chairs, plans company split amid...

Feb 27, 2025  0

J&J links FcRn blocker to sustained benefits as FDA ruling on potential blockbuster nears

J&J links FcRn blocker to sustained benefits as FDA rul...

Apr 8, 2025  0

Manufacturer fuels Swiss biotech’s next-gen vaccine portfolio in new investment deal

Manufacturer fuels Swiss biotech’s next-gen vaccine por...

Mar 12, 2025  0